Snehaa Organics IPO...
23 Aug, 2025
Anlon Healthcare Ltd IPO
Anlon Healthcare Ltd Mainboard IPO is going to hit the market on 26 August 2025 and closes on 29 August 2025. The price band for the issue has been fixed at ₹86 to ₹91 per share. The lot size for applying for the IPO is 164 shares. One can apply for 1 lot (164 shares) and multiples thereof. Anlon Healthcare IPO minimum application amount is ₹14,924 for the retailer. The company will raise a total of ₹121.03 crore through a 100% fresh issue of 1.33 crore equity shares, without any offer-for-sale. The allotment on September 1, 2025 and listing on NSE and BSE on September 3, 2025. Interactive Financial Services is the lead manager of the issue and KFin Technologies is the registrar to the issue.
Company Background
Anlon Healthcare Limited is a pharmaceutical manufacturer for the Indian formulators and export market and has its headquarters in Rajkot, Gujarat with the business being founded in 2013. The company's emphasis on process chemistry, documentation and adherence to global pharmacopeias, GMP-aligned systems in the product scaling and geography coverage scalability of the company. Conversion from a private to a public company in 2024 is also covered in the draft red herring prospectus, before its August 2025 listing timetable.
Operations & Product Range
Facility & Production
The organisation has multipurpose, GMP-compliant facilities around Rajkot, equipped to manage lab-to-plant scale-up and commercial production requirements, backed by utilities including solvent recovery and effluent treatment and QC instrumentation (HPLC/GC and wet labs) in line with statements made around API/intermediate production readiness. The process engineering team optimises the route, the impurity profile and the documentation so that technology transfers and validations can be conducted for both the client and various regulatory audits in India and certain export markets.
Brands & Market Presence
Being a B2B API/intermediates supplier, Anlon is not a consumer-facing name brand. Its “market presence” is primarily apparent in customer audits, DMF/documentation pathways and supply track records with domestic formulators and buyers in export markets, where purchasing teams assess quality systems and dossier completeness rather than retail brand identity.
Revenue Channels
- Supply of APIs & Intermediates to Indian Formulation Companies on a contractual basis/orders.
- Export sales into semi-regulated and regulated markets through documentation-backed SKUs.
- Custom synthesis /contract manufacturing for distinctive intermediates/APIs for B2B partners.
- Working capital-based scaling of volumes up with existing customers as new products are qualified.
Management & Shareholding
Promoters & Shareholding
The promoter group remains the majority owner pre-IPO(around 70.26%), which will be diluted proportionately with the fresh issue, yet they will drive strategic planning, capacity investment and regulatory filings, even as the company ramps up export-facing documentations and deliveries.
Board Members
The board is made up of executive directors from operations and strategy, as well as independent directors offering governance, finance and risk views. They serve to ensure that the company's internal controls and disclosures are consistent with the requirements of the mainboard listing.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Anlon Healthcare Ltd IPO
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Anlon Healthcare Ltd IPO Details
| Detail | Description |
|---|---|
| IPO Date | August 26, 2025 to August 29, 2025 |
| Listing Date | - |
| Face Value | ₹10 per share |
| Issue Price Band | ₹86 to ₹91 per share |
| Lot Size | 164 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 1,33,00,000 shares (aggregating up to ₹121.03 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,98,51,500 shares |
| Share Holding Post Issue | 5,31,51,500 shares |
Anlon Healthcare Ltd IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Tue, Aug 26, 2025 |
| IPO Close Date | Fri, Aug 29, 2025 |
| Tentative Allotment | Mon, Sep 1, 2025 |
| Initiation of Refunds | Tue, Sep 2, 2025 |
| Credit of Shares to Demat | Tue, Sep 2, 2025 |
| Tentative Listing Date | Wed, Sep 3, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 29, 2025 |
Anlon Healthcare Ltd IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Anlon Healthcare Ltd IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| Share Holding Pre Issue | 70.26% |
| Share Holding Post Issue | - |
Competitive Strength:
- ● End-to-end manufacturing capabilities from process development to the production of commercial API/intermediate under a GMP-driven system.
- ● “Documentation emphasis and regulatory portfolio allow for customer audits and access to a variety of geographies.
- ● Supplying through B2B relationships, domestic and export formulators that have repeat purchase attributes.
- ● Process engineering and QA/QC rigor enabling scale-up, cost improvements and quality consistency.
Anlon Healthcare Ltd IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 2025 | 160.96 | 77.37 | 11.96 | 71.86 | 62.39 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 128 | 67 | 10 | 21 | 74.56 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 111.55 | 113.12 | 5.82 | 7.37 | 66.39 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2022 | 84.97 | 57.54 | -0.11 | 1.55 | 60.32 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.21% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.38 | |
| P/E (x) | 14.26 |
IPO Objectives
- Capacity expansion and modernization of manufacturing facilities and utilities as outlined for scale-up.
- Working capital augmentation to support larger order books and export cycles.
- Debt reduction and general corporate purposes to strengthen the balance sheet and operations.
Conclusion
Anlon Healthcare IPO is positioned to fund scale-up in APIs and intermediates with a 100% fresh issue size of ₹121.03 crore under a price band of ₹86–₹91 and a minimum lot size of 164 shares to ensure the minimum ticket size remains in line with typical retail investors. The timeline through allotment September 1 and listing September 3 clearly establishes the path to trading, while the proceeds deployed towards capacity, working capital and balance-sheet strengthening enable the execution of a documentation-led, B2B driven growth plan in domestic and export markets.
RHP:
DRHP:
Read more :
Frequently asked Questions (FAQs )
-
● When does the IPO open and close?
It opens on August 26, 2025 and closes on August 29, 2025.
-
● How much is the issue size and what type of issue?
₹121.03 crore via a 100% fresh issue of 1.33 crore shares; no OFS.
-
● What is the tentative timeline for allotment and listing?
Basis of allotment on September 1; refunds/credit on September 2; listing on September 3, 2025.
-
● Which exchanges and who are the intermediaries?
Proposed listing on NSE and BSE; BRLM is an Interactive Financial Services and the registrar is KFin Technologies.
